menu
    • menu
    [{"orgOrder":0,"company":"Pharmazz","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Undisclosed"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Dr. Reddy's Laboratories","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Dr. Reddy's Laboratories","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Dr. Reddy's Laboratories"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Undisclosed"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Undisclosed"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Undisclosed"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Pharmazz \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Undisclosed"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pharmazz \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pharmazz \/ Undisclosed"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pharmazz \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Pharmazz \/ Undisclosed"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmazz \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Undisclosed"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmazz \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Undisclosed"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmazz \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Undisclosed"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Adrenergic-alpha-2 receptor","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pharmazz \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Pharmazz \/ Undisclosed"},{"orgOrder":0,"company":"Pharmazz","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Centhaquine","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pharmazz","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pharmazz \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pharmazz \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals for Centhaquine

    Menu

    Centhaquine

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Pharmazz

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Pharmazz

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Centhaquine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved FDF

                            Sponsor : Dr. Reddy\'s Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Pharmazz and Dr. Reddy’s to Market Centhaquine as Resuscitative Agent for Shock in India

                            Details : Under the agreement, Dr. Reddy's has exclusive rights to market and distribute Lyfaquin, an innovative drug developed by Pharmazz, indicated for hypovolemic shock treatment.

                            Product Name : Lyfaquin

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            March 22, 2024

                            Lead Product(s) : Centhaquine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved FDF

                            Sponsor : Dr. Reddy\'s Laboratories

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Pharmazz

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Pharmazz

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Centhaquine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess the Safety and Efficacy of Centhaquine in Hypovolemic Shock Patients

                            Details : Centhaquine is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Shock.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 21, 2023

                            Lead Product(s) : Centhaquine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Pharmazz

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Pharmazz

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Centhaquine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmazz Inc. Presents Data From its Positive Phase III Study of Centhaquine (PMZ-2010) as a Resuscitative Age...

                            Details : The positive results seen in the Phase III study indicate that Lyfaquin (centhaquine) is a highly safe and efficacious resuscitative agent as an adjuvant to the standard of care and would be a addition to the U.S. Military’s medical resources that can ...

                            Product Name : Lyfaquin

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 13, 2022

                            Lead Product(s) : Centhaquine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Pharmazz

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Pharmazz

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Centhaquine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study to Assess Safety and Efficacy of Centhaquine as a Resuscitative Agent

                            Details : Centhaquine is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Shock.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 22, 2022

                            Lead Product(s) : Centhaquine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Pharmazz

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Pharmazz

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Centhaquine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Multicentric, Randomized Study to Assess Safety and Efficacy of Centhaquine in COVID-19 Patients With ARDS

                            Details : Centhaquine is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 15, 2022

                            Lead Product(s) : Centhaquine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Pharmazz

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Pharmazz

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Centhaquine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            US FDA Approved IND Submitted by Pharmazz, Inc. to Initiate a Phase III Clinical Trial of Centhaquine in Patie...

                            Details : Centhaquine converts the venous unstressed blood volume to stressed blood volume and improves cardiac output and blood circulation. Centhaquine (Lyfaquin®) as a Resuscitative Agent in Hypovolemic Shock Patients.

                            Product Name : Lyfaquin

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 29, 2021

                            Lead Product(s) : Centhaquine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Pharmazz

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Pharmazz

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Centhaquine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Resuscitative Effect of Centhaquine (Lyfaquin®) in Hypovolemic Shock Patients: A Randomized, Multicentric, Co...

                            Details : Lyfaquin® is a frontline therapy used in conjunction with the standard of care and is well-positioned to address critical unmet needs in hypovolemic shock. The Company is marketing Centhaquine Citrate, with the brand name Lyfaquin® to health care profe...

                            Product Name : Lyfaquin

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 10, 2021

                            Lead Product(s) : Centhaquine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Pharmazz

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Pharmazz

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Centhaquine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lyfaquin®, a First-in-class Resuscitative Agent for Patients with Excessive Blood Loss, to be Launched in Ind...

                            Details : Lyfaquin® increases blood pressure and cardiac output by augmenting venous blood return to the heart and enhancing tissue blood perfusion by arterial dilatation (sympatholytic function due to central alpha-2A adrenergic stimulation).

                            Product Name : Lyfaquin

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            July 20, 2020

                            Lead Product(s) : Centhaquine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Pharmazz

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Pharmazz

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Centhaquine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmazz Receives Marketing Authorization for Lyfaquin™ (centhaquine) from Indian Regulatory Agency

                            Details : Centhaquine's pivotal phase III study in India in hypovolemic shock demonstrated a transformational improvement over standard of care in increasing blood pressure and reducing blood lactate levels.

                            Product Name : Lyfaquin

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            May 14, 2020

                            Lead Product(s) : Centhaquine

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Pharmazz

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Pharmazz

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Centhaquine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Pharmazz Highlights Positive Impacts of Centhaquine on COVID-19 Patients.

                            Details : Pharmazz has completed a multi-centric phase 3 study to assess the efficacy of centhaquine as a resuscitative agent to be used as an adjuvant to standard treatment in hypovolemic shock patients.

                            Product Name : Lyfaquin

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 09, 2020

                            Lead Product(s) : Centhaquine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Undisclosed

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth